Trial Profile
Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Mycophenolate mofetil
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- Acronyms The OFA3 trial
- 18 Oct 2018 New trial record